PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11316974-0 2001 Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Flutamide 26-35 gonadotropin releasing hormone 1 Homo sapiens 104-134 16980238-2 2006 Based upon this observation, two important discoveries also made by our group are applied worlwide, namely the use of GnRH (gonadotropin -releasing hormone) agonists that completely block testicular androgen secretion, while, simultaneously, the androgens made locally in the prostate from DHEA are blocked in their access to the androgen receptor by a pure antiandrogen (flutamide, bicalutamide or nilutamide). Flutamide 372-381 gonadotropin releasing hormone 1 Homo sapiens 118-122 16980238-2 2006 Based upon this observation, two important discoveries also made by our group are applied worlwide, namely the use of GnRH (gonadotropin -releasing hormone) agonists that completely block testicular androgen secretion, while, simultaneously, the androgens made locally in the prostate from DHEA are blocked in their access to the androgen receptor by a pure antiandrogen (flutamide, bicalutamide or nilutamide). Flutamide 372-381 gonadotropin releasing hormone 1 Homo sapiens 124-155 12536355-7 2002 This abnormality is reversed by the androgen receptor antagonist flutamide, suggesting that elevated androgen levels may alter the sensitivity of the hypothalamic GnRH pulse generator to steroid inhibition and lead to enhanced LH secretion. Flutamide 65-74 gonadotropin releasing hormone 1 Homo sapiens 163-167 11095431-0 2000 Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. Flutamide 43-52 gonadotropin releasing hormone 1 Homo sapiens 81-111 9170575-1 1996 BACKGROUND: In a recent study by the Casodex Combination Study Group, USA, patients in a flutamide (750 mg/day) plus LH-RH agonist group showed a high treatment failure rate, mainly due to flutamide-induced diarrhea and hepatotoxicity. Flutamide 189-198 gonadotropin releasing hormone 1 Homo sapiens 117-122 9761805-2 1998 In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. Flutamide 59-68 gonadotropin releasing hormone 1 Homo sapiens 104-134 2144819-0 1990 Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate. Flutamide 61-70 gonadotropin releasing hormone 1 Homo sapiens 99-103 8977067-0 1996 Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. Flutamide 27-36 gonadotropin releasing hormone 1 Homo sapiens 78-82 7538237-6 1995 Patients in the flutamide plus LHRH-A group were 34% more likely to fail treatment over the given time period, as indicated by the hazard ratio of 0.749 (95% confidence interval, 0.61 to 0.92) for bicalutamide plus LHRH-A to flutamide plus LHRH-A. Flutamide 16-25 gonadotropin releasing hormone 1 Homo sapiens 215-219 7538237-6 1995 Patients in the flutamide plus LHRH-A group were 34% more likely to fail treatment over the given time period, as indicated by the hazard ratio of 0.749 (95% confidence interval, 0.61 to 0.92) for bicalutamide plus LHRH-A to flutamide plus LHRH-A. Flutamide 16-25 gonadotropin releasing hormone 1 Homo sapiens 215-219 7538237-6 1995 Patients in the flutamide plus LHRH-A group were 34% more likely to fail treatment over the given time period, as indicated by the hazard ratio of 0.749 (95% confidence interval, 0.61 to 0.92) for bicalutamide plus LHRH-A to flutamide plus LHRH-A. Flutamide 225-234 gonadotropin releasing hormone 1 Homo sapiens 31-35 8111715-3 1994 One of the most popular agents is leuprolide (with or without flutamide), an agonist of luteinizing hormone-releasing hormone (LH-RH). Flutamide 62-71 gonadotropin releasing hormone 1 Homo sapiens 88-125 1794008-6 1991 Thus, while there seems to be little doubt that flutamide prevents the initial disease flare caused by GnRH agonists, an improvement in remission rate and survival remains contentious. Flutamide 48-57 gonadotropin releasing hormone 1 Homo sapiens 103-107 2193461-3 1990 Clinical studies in prostate cancer patients have demonstrated efficacy with flutamide monotherapy in patients who had received no prior treatment, in untreated patients with combined androgen blockade concomitantly with a luteinizing hormone-releasing hormone (LHRH)-agonist, and in relapsed patients. Flutamide 77-86 gonadotropin releasing hormone 1 Homo sapiens 262-266 2193461-5 1990 When given as monotherapy and in combination with an LHRH-agonist, flutamide is well tolerated. Flutamide 67-76 gonadotropin releasing hormone 1 Homo sapiens 53-57 2144819-1 1990 The aim of the present investigation was to establish whether in advanced prostatic carcinoma in relapse treated with LHRH analogues combined with cyproterone acetate (CPA), substitution of this antiandrogen with another compound such as flutamide (FLU) might lead to further subjective and objective improvement. Flutamide 238-247 gonadotropin releasing hormone 1 Homo sapiens 118-122 3283766-14 1988 Considering the excellent tolerance coupled with an objective response observed in 34.5% of the patients, the combination therapy with Flutamide and castration (surgical or LHRH agonist) appears to be the treatment of choice for prostate cancer patients in relapse after standard endocrine therapy. Flutamide 135-144 gonadotropin releasing hormone 1 Homo sapiens 173-177 2670515-12 1989 In combination with an LHRH agonist flutamide may become a first-line agent for previously untreated patients with cancer of the prostate. Flutamide 36-45 gonadotropin releasing hormone 1 Homo sapiens 23-27 3286322-3 1988 Of major significance is the finding that the changes in serum T levels observed during the first 3 weeks of treatment, as well as the complete inhibition of the intratesticular concentration of sex steroids observed at the end of this period of treatment with the LHRH agonist were not affected by simultaneous administration of flutamide (125 mg per os every 8 h). Flutamide 330-339 gonadotropin releasing hormone 1 Homo sapiens 265-269 3279409-0 1988 Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Flutamide 25-34 gonadotropin releasing hormone 1 Homo sapiens 113-117 3285484-12 1988 The largest and best study to date is the Southwest Oncology Group (SWOG) study, which did show a near-significant (P less than 0.065) difference between patients treated for 20 months with a luteinizing hormone-releasing hormone (LH-RH) plus flutamide compared with LH-RH alone. Flutamide 243-252 gonadotropin releasing hormone 1 Homo sapiens 231-236 3100871-14 1986 Patients already castrated received only Flutamide while, for those previously treated with DES, the estrogen was replaced by the LHRH agonist [D-Trp6]LHRH ethylamide in association with Flutamide. Flutamide 187-196 gonadotropin releasing hormone 1 Homo sapiens 130-134 3100871-14 1986 Patients already castrated received only Flutamide while, for those previously treated with DES, the estrogen was replaced by the LHRH agonist [D-Trp6]LHRH ethylamide in association with Flutamide. Flutamide 187-196 gonadotropin releasing hormone 1 Homo sapiens 151-155 2934579-0 1985 Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. Flutamide 25-34 gonadotropin releasing hormone 1 Homo sapiens 51-55